Ed Arce

H.C. Wainwright & Co.

Image: Ed Arce

Ed Arce is a managing director in equity research and a senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright & Co. Previously, Arce was a senior research analyst with ROTH Capital Partners. Prior to ROTH, he covered biotechnology, biopharmaceutical, specialty pharmaceutical and select medical device companies as an analyst at MLV & Co. Prior to MLV, Arce covered the biotechnology sector at Wedbush Securities, and large-cap pharmaceuticals at UBS Securities. Arce started his equity research career in 2005 as a research associate at First Albany Capital, covering specialty and generic pharmaceutical companies.
He holds a master of science degree in finance (MSF) degree from Boston College, as well as a master's degree in business administration and a bachelor's degree in civil engineering, both from Florida International University. Mr. Arce is a board-licensed professional engineer, and a Level III CFA candidate.

Recent Articles

Biotech Co. Nearing Milestones for HBV Drugs 08/15/2022

Arbutus Biopharma Corp. presented clinical data to an international liver disease conference showing that its AB-729 continues to deliver strong reductions in HBsAg. The company is now conducting three separate combination therapy studies of its AB-729 and expects to achieve important milestones when the initial data readouts are released in H2/22. H.C. Wainwright & Co. affirmed its Buy rating for Arbutus Biopharma and adjusted its price target to $7.50.

Recent Quotes

"DRRX's Phase 2b DUR-928 AH trial is set to begin in mid-2020."

— Ed Arce, H.C. Wainwright & Co. (3/4/20)
more >

"From a stock perspective, 2019 was a clear breakout year for DRRX."

— Ed Arce, H.C. Wainwright & Co. (1/3/20)
more >

"DRRX has a valuable greenfield opportunity here with DUR-928."

— Ed Arce, H.C. Wainwright & Co. (11/25/19)
more >

"An AdCom meeting for DRRX's POSIMIR is scheduled for Jan. 16, 2020."

— Ed Arce, H.C. Wainwright & Co. (11/20/19)
more >

"DRRX's psoriasis trial is on target for topline data by year-end 2019."

— Ed Arce, H.C. Wainwright & Co. (11/3/19)
more >

"DRRX's DUR-928 treatment led to improved prognosis in AH patients."

— Ed Arce, H.C. Wainwright & Co. (9/18/19)
more >

"DRRX earned a $10M milestone payment from Gilead."

— Ed Arce, H.C. Wainwright & Co. (9/10/19)
more >

"We expect substantial news flow from DRRX over the next five months."

— Ed Arce, H.C. Wainwright & Co. (8/2/19)
more >

Due to permission requirements, not all quotes are shown.